Dupilumab Compassionate Use Study
1 other identifier
expanded_access
N/A
0 countries
N/A
Brief Summary
This is a single patient expanded access, compassionate and non-emergency use study that provides patients with severe asthma, who do not qualify for ongoing clinical trials with dupilumab, access to this investigational treatment.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 11, 2017
CompletedFirst Posted
Study publicly available on registry
January 13, 2017
CompletedMarch 7, 2018
March 1, 2018
January 11, 2017
March 5, 2018
Conditions
Interventions
The patient will receive a 600 mg subcutaneous dupilumab loading dose on Day 1, and then 300 mg subcutaneous dupilumab every 2 weeks
Eligibility Criteria
You may qualify if:
- Sever systemic corticosteroid dependent asthma for more than 5 years
You may not qualify if:
- Disease other than asthma
- Circulation eosinophils more than 1500/ul
- Current smoker or more than 10 pack years
- This is a single-patient study. The University of Pittsburgh site is not enrolling new patients.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- expanded access
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor of Medicine
Study Record Dates
First Submitted
January 11, 2017
First Posted
January 13, 2017
Last Updated
March 7, 2018
Record last verified: 2018-03